Dr. Niihara is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
21840 Normandie Ave
Ste. 700
Torrance, CA 90502Phone+1 310-222-5101Fax+1 310-320-5463
Education & Training
Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 1989 - 1990
Kettering Health Network/Kettering Medical CenterResidency, Internal Medicine, 1986 - 1989
Loma Linda University School of MedicineClass of 1986
Certifications & Licensure
OH State Medical License 1987 - 2026
CA State Medical License 1988 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia Start of enrollment: 2004 Mar 01
- L-Glutamine Therapy for Sickle Cell Anemia Start of enrollment: 2004 Feb 06
Publications & Presentations
PubMed
- 153 citationsA Phase 3 Trial of l-Glutamine in Sickle Cell Disease.Yutaka Niihara, Scott T Miller, Julie Kanter, Sophie Lanzkron, Wally R Smith
The New England Journal of Medicine. 2018-07-19 - 15 citationsClinical Trials of Limbal Stem Cell Deficiency Treated with Oral Mucosal Epithelial Cells.Joan Oliva, Fawzia Bardag-Gorce, Yutaka Niihara
International Journal of Molecular Sciences. 2020-01-09 - 98 citationsOral L‐glutamine therapy for sickle cell anemia: I. subjective clinical improvement and favorable change in red cell NAD redox potentialYutaka Niihara, Charles R. Zerez, Dean S. Akiyama, Kouichi R. Tanaka
American Journal of Hematology. 1998-06-01
Journal Articles
- A Phase 3 Trial of L-glutamine in Sickle Cell DiseaseRita Bellevue, Joseph L Lasky, Elliott P Vichinsky, Lewis L Hsu, Sharada Sarnaik, Lynne D Neumayr, Yutaka Niihara, Sophie Lanzkron, Ifeyinwa Osunkwo, Lance Sieger, Edu..., The New England Journal of Medicine
Press Mentions
Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for HaematologyApril 7th, 2022- Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect ConferenceJanuary 4th, 2022
- Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor from Kainos MedicineOctober 12th, 2021
- Join now to see all
Grant Support
- Clinical Trial: L-Glutamine Therepy For Sickle Cell AnemiaNational Center For Research Resources2008–2010
- L-Glutamine Therapy For Sickle Cell AnemiaNational Center For Research Resources2004–2009
- Clinical Trial: L-Glutamine Therapy For Sickle Cell AnemiaNational Center For Research Resources2008
- L-Glutamine Therapy For Sickle Cell AnemiaFood And Drug Administration2005
- Oral L-Glutamine Therapy For Sickle Cell AnemiaNational Center For Research Resources2004
- Oral L Glutamine Therapy For Sickle Cell AnemiaNational Center For Research Resources1999–2001
- Glutamine Supplements On Pyridine Nucleotides &Survival Of Sickle Red BloodNational Center For Research Resources1999–2001
- Oral L Glutamine Therapy For Sickle Cell AnemiaNational Heart, Lung, And Blood Institute1998–2001
- Aged Garlic Extract Therapy For Sickle Cell Anemic PatientsNational Center For Research Resources2000
- Glutamine Supplements On Pyridine Nucleotides &Survival Of Sickle Red Blood CENational Center For Research Resources1997–1999
- Glutamine Supplements On Pyridine Nucleotides &Sickle Cell AnemiaNational Center For Research Resources1996
Professional Memberships
- Member
Other Languages
- Japanese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
